BO1 Overzicht aandelen BioCryst Pharmaceuticals, Inc. is een biotechnologiebedrijf dat orale therapeutica op basis van kleine moleculen en eiwitten ontwikkelt voor de behandeling van zeldzame ziekten. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
BioCryst Pharmaceuticals, Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor BioCryst Pharmaceuticals Historische aandelenkoersen Huidige aandelenkoers US$7.07 52 Week Hoogtepunt US$7.82 52 Week Laag US$3.84 Bèta 1.77 1 maand verandering -2.48% 3 maanden verandering -2.10% 1 Jaar Verandering 36.70% 3 jaar verandering -41.21% 5 jaar verandering 152.50% Verandering sinds IPO 54.98%
Recent nieuws en updates
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
New minor risk - Share price stability Nov 17
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05
Third quarter 2024 earnings released: US$0.068 loss per share (vs US$0.19 loss in 3Q 2023) Nov 05
BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat) Oct 14 Meer updates bekijken
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
New minor risk - Share price stability Nov 17
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05
Third quarter 2024 earnings released: US$0.068 loss per share (vs US$0.19 loss in 3Q 2023) Nov 05
BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat) Oct 14
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome Oct 02
Insufficient new directors Oct 01
BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat) Sep 17
Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer Sep 05
Second quarter 2024 earnings released: US$0.061 loss per share (vs US$0.40 loss in 2Q 2023) Aug 06
BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 Aug 05
BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 22
New major risk - Share price stability May 31
Senior VP recently bought €187k worth of stock May 16
BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO May 15
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO May 10 Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 May 08
First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.28 loss in 1Q 2023) May 06
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 23
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency Apr 17
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 Feb 29
Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022) Feb 26
BioCryst Launches Orladeyo (Berotralstat) in Italy Feb 20
BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 13
Forecast breakeven date pushed back to 2026 Jan 09
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 Jan 06
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat) Dec 19
New major risk - Share price stability Dec 08
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023 Dec 01
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina Nov 29
BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO Nov 22
BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat) Nov 11
New minor risk - Shareholder dilution Nov 10
No longer forecast to breakeven Nov 04
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023 Nov 03
No longer forecast to breakeven Nov 03
BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology Oct 28
Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013 Oct 27
BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec Sep 19
Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022) Aug 04
BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Biocryst Pharmaceuticals, Inc. Announces Executive Changes Jul 12
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile May 23
First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.40 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$1.33 loss per share (vs US$1.03 loss in FY 2021) Feb 22
BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 08
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema Jan 27
BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases Jan 10
Forecast to breakeven in 2025 Dec 31
BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health Nov 29
High number of new directors Nov 16
Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy Nov 11
Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.33 loss in 3Q 2021) Nov 02
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022 Nov 02
BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer Sep 15
FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva Sep 01
Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients Aug 27
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia Aug 19
BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program Aug 06
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021) Aug 05
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 05
BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) Jul 02
BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 Jun 23
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 10
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 09
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic Jun 08
Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks Jun 07
First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 1Q 2021) May 06
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022 May 06
European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva Apr 28
High number of new directors Apr 27
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022 Apr 26
BioCryst Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
BioCryst Pharmaceuticals, Inc. Pauses Enrollment in BCX9930 Clinical Trials Apr 09
High number of new directors Apr 01
High number of new directors Mar 02
Biocryst Pharmaceuticals, Inc. Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among Hae Patients Following Long-Term Treatment with Orladeyo Feb 25
No longer forecast to breakeven Feb 25
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 24 BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022
BioCryst Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 10
BioCryst Appoints Machelle Sanders to Board of Directors Feb 09
BioCryst Pharmaceuticals, Inc. Provides ORLADEYO Net Revenue and Peak Sales Guidance for Full Year 2022 Jan 12
BioCryst Pharmaceuticals, Inc. Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Jan 09
Forecast to breakeven in 2024 Jan 01
BioCryst Pharmaceuticals, Inc Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Dec 01
Director recently bought €82k worth of stock Nov 25
Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.26 loss in 3Q 2020) Nov 04
High number of new directors Sep 14
High number of new directors Sep 04
High number of new directors Sep 02
BioCryst Pharmaceuticals, Inc. Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic Aug 26 Rendement voor aandeelhouders BO1 DE Biotechs DE Markt 7D -2.1% -2.9% -2.6% 1Y 36.7% -14.7% 6.9%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: BO1 overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -14.7 % opleverde.
Rendement versus markt: BO1 overtrof de German markt, die het afgelopen jaar een rendement opleverde van 6.9 %.
Prijsvolatiliteit Is BO1's price volatile compared to industry and market? BO1 volatility BO1 Average Weekly Movement 7.3% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stabiele aandelenkoers: De aandelenkoers van BO1 is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van BO1 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.
Over het bedrijf BioCryst Pharmaceuticals, Inc., een biotechnologiebedrijf, ontwikkelt orale therapeutica op basis van kleine moleculen en eiwitten voor de behandeling van zeldzame ziekten. Het bedrijf brengt peramivir injectie op de markt, een intraveneuze neuraminidaseremmer voor de behandeling van acute ongecompliceerde griep onder de namen RAPIVAB, RAPIACTA en PERAMIFLU; en ORLADEYO, een orale serineproteaseremmer voor de behandeling van erfelijk angio-oedeem. Het ontwikkelt ook BCX10013, een orale factor D-remmer voor complementgemedieerde ziekten.
Meer tonen BioCryst Pharmaceuticals, Inc. Samenvatting Hoe verhouden de winst en inkomsten van BioCryst Pharmaceuticals zich tot de beurswaarde? BO1 fundamentele statistieken Marktkapitalisatie €1.50b Inkomsten(TTM ) -€118.67m Inkomsten(TTM ) €395.42m
3.8x P/S-verhouding
-12.7x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) BO1 resultatenrekening (TTM ) Inkomsten US$412.58m Kosten van inkomsten US$197.47m Brutowinst US$215.11m Overige uitgaven US$338.93m Inkomsten -US$123.82m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.60 Brutomarge 52.14% Nettowinstmarge -30.01% Schuld/Eigen Vermogen Verhouding -176.9%
Hoe presteerde BO1 op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/22 11:13 Aandelenkoers aan het einde van de dag 2024/12/20 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten BioCryst Pharmaceuticals, Inc. wordt gevolgd door 30 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Huidong Wang Barclays Tazeen Ahmad BofA Global Research Dae Gon Ha BTIG
Toon 27 meer analisten 
